

# Ricardo G Alvim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7072875/publications.pdf>

Version: 2024-02-01

18  
papers

214  
citations

1478505

6  
h-index

1058476

14  
g-index

18  
all docs

18  
docs citations

18  
times ranked

358  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2022, 208, 813-820.	0.4	8
2	Positron Emission Tomography/Computed Tomography with Gallium-68 <sup>68</sup> labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model. <i>European Urology Focus</i> , 2021, 7, 472-478.	3.1	4
3	Focal therapy for primary and salvage prostate cancer treatment: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3144-3154.	1.4	0
4	Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer. <i>Scientific Reports</i> , 2021, 11, 4842.	3.3	4
5	Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model. <i>Molecules</i> , 2021, 26, 3744.	3.8	8
6	Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management. <i>Urology</i> , 2021, , .	1.0	0
7	A comparison of oncologic and functional outcomes in patients with pt3a renal cell carcinoma treated with partial and radical nephrectomy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 777-783.	1.5	6
8	Extensive disease among potential candidates for hemi <sup>68</sup> ablative focal therapy for prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 179-185.	1.0	1
9	Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies. <i>Molecules</i> , 2020, 25, 5417.	3.8	11
10	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975.	12.8	37
11	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Journal of Urology</i> , 2020, 203, 1122-1127.	0.4	58
12	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. <i>Journal of Urology</i> , 2020, 203, 1117-1121.	0.4	28
13	Combined OX40 agonist and PD-1 inhibitor immunotherapy improves the efficacy of vascular targeted photodynamic therapy in a urothelial tumor model.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17004-e17004.	1.6	3
14	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 1121-1121.	0.4	0
15	Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. <i>European Urology Focus</i> , 2019, 5, 977-979.	3.1	5
16	The potential risk of tumor progression after use of dehydrated human amnion/chorion membrane allograft in a positive margin resection model. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721983777.	2.0	6
17	Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. <i>Oncolmmunology</i> , 2019, 8, e1581528.	4.6	20
18	Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. <i>European Urology Oncology</i> , 2018, 1, 428-434.	5.4	15